Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study.

Shin FukudoHiroto MiwaAtsushi NakajimaYoshikazu KinoshitaMasanori KosakoAyako NakagawaHiraku AkihoKentaro KuroishiJeffrey M JohnstonMark CurrieToshifumi Ohkusa

Published in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2018)

Our results suggest that 0.0625, 0.125, 0.25, and 0.5 mg/d are effective doses of linaclotide for treating CC in Japanese patients. ClinicalTrials.gov: NCT02425722, supported by Astellas Pharma, Inc.

Keyphrases

double blind
phase ii
placebo controlled
clinical trial
open label
phase iii
study protocol
randomized controlled trial